Solid biosciences provides fourth quarter and full-year 2023 business update and financial results

— company ends 2023 with approximately $123.6 million in cash and investments. combined with gross proceeds from $108.9 million private placement in january, solid has anticipated cash runway into 2026 —

SLDB Ratings Summary

SLDB Quant Ranking